Hitting a new 52-week low can be a pivotal moment for any stock. These floors often mark either the beginning of a turnaround story or confirmation that a company faces serious headwinds.

While market timing can be an extremely profitable strategy, it has burned many investors and requires rigorous analysis - something we specialize in at StockStory. Keeping that in mind, here is one stock poised to prove the bears wrong and two facing legitimate challenges.

Two Stocks to Sell:

Box (BOX)

One-Month Return: -13.9%

Known as the "Content Cloud" for managing the 90% of business data that exists as unstructured files and documents, Box (NYSE: BOX) provides a cloud-based platform that enables organizations to securely manage, share, and collaborate on their content from anywhere on any device.

Why Does BOX Worry Us?

1. Products, pricing, or go-to-market strategy may need some adjustments as its 11.9% average billings growth over the last year was weak
2. Projected sales growth of 7.7% for the next 12 months suggests sluggish demand
3. Expenses have increased as a percentage of revenue over the last year as its operating margin fell by 1.6 percentage points

At $24.58 per share, Box trades at 2.9x forward price-to-sales. To fully understand why you should be careful with BOX, check out our full research report (it’s free).

GoodRx (GDRX)

One-Month Return: -21.4%

Started in 2011 to tackle the problem of high prescription drug costs in America, GoodRx (NASDAQ: GDRX) operates a digital platform that helps consumers find lower prices on prescription medications through price comparison tools and discount codes.

Why Do We Steer Clear of GDRX?

1. Underwhelming customer growth over the past two years shows the company faced challenges in winning new contracts
2. Modest revenue base of $800.7 million gives it less fixed cost leverage and fewer distribution channels than larger companies
3. Push for growth has led to negative returns on capital, signaling value destruction

GoodRx is trading at $2.23 per share, or 5.4x forward P/E. If you’re considering GDRX for your portfolio, see our FREE research report to learn more.

One Stock to Buy:

Humana (HUM)

One-Month Return: -30.1%

With over 80% of its revenue derived from federal government contracts, Humana (NYSE: HUM) provides health insurance plans and healthcare services to approximately 17 million members, with a strong focus on Medicare Advantage plans for seniors.

Why Are We Backing HUM?

1. Solid 12.8% annual revenue growth over the last two years indicates its offering’s solve complex business issues
2. Enormous revenue base of $126.3 billion gives it leverage over plan holders and advantageous reimbursement terms with healthcare providers
3. ROIC punches in at 34.4%, illustrating management’s expertise in identifying profitable investments

Humana’s stock price of $192.72 implies a valuation ratio of 14.4x forward P/E. Is now a good time to buy? See for yourself in our full research report, it’s free.

Stocks We Like Even More

Your portfolio can’t afford to be based on yesterday’s story. The risk in a handful of heavily crowded stocks is rising daily.

The names generating the next wave of massive growth are right here in our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.